Amedisys Inc (NASDAQ:AMED) Shares Bought by State Street Corp

State Street Corp lifted its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 4.1% during the third quarter, Holdings Channel reports. The fund owned 1,009,576 shares of the health services provider’s stock after purchasing an additional 39,594 shares during the quarter. State Street Corp’s holdings in Amedisys were worth $132,265,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Voya Financial Advisors Inc. boosted its holdings in Amedisys by 10.1% in the third quarter. Voya Financial Advisors Inc. now owns 4,890 shares of the health services provider’s stock valued at $631,000 after purchasing an additional 447 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of Amedisys by 9.8% during the 3rd quarter. Voya Investment Management LLC now owns 601,676 shares of the health services provider’s stock valued at $78,825,000 after buying an additional 53,618 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its stake in shares of Amedisys by 10.3% during the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 9,175 shares of the health services provider’s stock valued at $1,202,000 after buying an additional 859 shares during the last quarter. Great Lakes Advisors LLC grew its position in shares of Amedisys by 4.3% during the third quarter. Great Lakes Advisors LLC now owns 70,111 shares of the health services provider’s stock worth $9,185,000 after buying an additional 2,901 shares in the last quarter. Finally, Boston Advisors LLC grew its position in shares of Amedisys by 1.8% during the third quarter. Boston Advisors LLC now owns 47,529 shares of the health services provider’s stock worth $6,227,000 after buying an additional 852 shares in the last quarter. 90.90% of the stock is currently owned by institutional investors and hedge funds.

AMED has been the topic of several recent analyst reports. Stephens reaffirmed an “equal weight” rating and issued a $145.00 price target on shares of Amedisys in a report on Tuesday, October 22nd. ValuEngine lowered shares of Amedisys from a “buy” rating to a “hold” rating in a report on Thursday, September 26th. Bank of America boosted their target price on shares of Amedisys from $170.00 to $178.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Deutsche Bank started coverage on shares of Amedisys in a research report on Monday, September 16th. They issued a “buy” rating and a $155.00 target price for the company. Finally, BMO Capital Markets started coverage on shares of Amedisys in a research note on Friday. They issued a “market perform” rating and a $170.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $148.83.

In other Amedisys news, Director Donald A. Washburn sold 8,667 shares of Amedisys stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $149.96, for a total value of $1,299,703.32. Following the completion of the transaction, the director now directly owns 36,698 shares in the company, valued at $5,503,232.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott G. Ginn sold 7,690 shares of Amedisys stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $145.17, for a total value of $1,116,357.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,757 shares of company stock worth $2,616,156. 2.90% of the stock is owned by company insiders.

AMED stock opened at $166.85 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.95 and a quick ratio of 0.95. Amedisys Inc has a 1-year low of $103.76 and a 1-year high of $167.87. The firm has a fifty day moving average price of $149.34 and a two-hundred day moving average price of $131.78. The firm has a market cap of $5.38 billion, a price-to-earnings ratio of 45.96, a PEG ratio of 2.26 and a beta of 1.47.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, October 29th. The health services provider reported $1.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.90 by $0.25. Amedisys had a net margin of 6.70% and a return on equity of 26.53%. The company had revenue of $494.63 million for the quarter, compared to the consensus estimate of $494.14 million. During the same period last year, the firm posted $0.95 EPS. The company’s revenue for the quarter was up 18.5% on a year-over-year basis. As a group, analysts expect that Amedisys Inc will post 4.39 EPS for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Further Reading: Are we seeing the beginning of a new bubble?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit